ClinicalThought

Share

Program Content

Activities

  • Next-Gen BTK Inhibitors
    Next-Generation BTK Inhibitors and Why We Need Them
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2019

    Expires: October 22, 2020

  • BTK Inhibitor FAQs
    Frequently Asked Questions About BTK Inhibitor Use in B-Cell Malignancies
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 21, 2020

    Expires: February 19, 2021

  • Zanubrutinib in MCL
    Meet Zanubrutinib, the Newest Bruton’s Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 24, 2020

    Expires: March 23, 2021

Faculty

cover img faculity

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

cover img faculity

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

ProCE Banner

Supporters

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly